TVTX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
TVTX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
As of today, Travere Therapeutics's Trailing 12-Month Free Cash Flow is $-338.7 Mil, and Market Cap is $1,547.6 Mil. Therefore, Travere Therapeutics's FCF Yield % for today is -21.88%.
The historical rank and industry rank for Travere Therapeutics's FCF Yield % or its related term are showing as below:
During the past 13 years, the highest FCF Yield % of Travere Therapeutics was -0.64%. The lowest was -83.31%. And the median was -6.58%.
Travere Therapeutics's FCF Margin % for the quarter that ended in Dec. 2024 was -60.55%.
The historical data trend for Travere Therapeutics's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Travere Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||||
FCF Yield % | Get a 7-Day Free Trial |
![]() |
![]() |
-11.42 | -2.01 | -15.88 | -47.47 | -22.23 |
Travere Therapeutics Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
FCF Yield % | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
-44.47 | -85.53 | -74.62 | -18.61 | -11.89 |
For the Biotechnology subindustry, Travere Therapeutics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Travere Therapeutics's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Travere Therapeutics's FCF Yield % falls into.
FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Travere Therapeutics's FCF Yield % for the fiscal year that ended in Dec. 2024 is calculated as
FCF Yield % | = | Free Cash Flow | / | Market Cap |
= | -338.687 | / | 1523.43126 | |
= | -22.23% |
Travere Therapeutics's annualized FCF Yield % for the quarter that ended in Dec. 2024 is calculated as
FCF Yield % | = | Free Cash Flow | * | Annualized Factor | / | Market Cap |
= | -45.281 | * | 4 | / | 1523.43126 | |
= | -11.89% |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Travere Therapeutics FCF Yield % Explanation
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Thank you for viewing the detailed overview of Travere Therapeutics's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.
Jula Inrig | officer: Chief Medical Officer | C/O TRAVERE THERAPEUTICS, INC., 3611 VALLEY CENTRE DRIVE, SUITE 300, SAN DIEGO CA 92130 |
William E. Rote | officer: Senior Vice President, R&D | C/O RETROPHIN, INC., 3721 VALLEY CENTRE DRIVE, SUITE 200, SAN DIEGO CA 92130 |
Peter Heerma | officer: Chief Commercial Officer | C/O TRAVERE THERAPEUTICS, INC., 3611 VALLEY CENTRE DRIVE, SUITE 300, SAN DIEGO CA 92130 |
Elizabeth E Reed | officer: SVP, GC & Corporate Secretary | 9050 CAMINO SANTA FE, SAN DIEGO CA 92121 |
Sandra Calvin | officer: VP, Corp Controller and CAO | 3611 VALLEY CENTER DRIVE, SUITE 300, SAN DIEGO CA 92130 |
Eric M Dube | director, officer: Chief Executive Officer | 3721 VALLEY CENTRE DRIVE, SUITE 200, SAN DIEGO CA 92130 |
Roy D. Baynes | director | C/O RETROPHIN, INC., 12255 EL CAMINO REAL, SUITE 250, SAN DIEGO CA 92130 |
Christopher R. Cline | officer: Chief Financial Officer | C/O TRAVERE THERAPEUTICS, INC., 3611 VALLEY CENTRE DRIVE, STE 300, SAN DIEGO CA 92130 |
Gary A Lyons | director | 12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130 |
Jeffrey A Meckler | director | 740 BROADWAY, 9TH FLOOR, NEW YORK NY 10003 |
Laura Clague | officer: Chief Financial Officer | 370 PARK RANCH PLACE, ESCONDIDO CA 92025 |
Steve Aselage | director | 6300 DUMBARTON CIRCLE, FREMONT CA 94555 |
Brinkley Ruth Williams | director | C/O TRAVERE THERAPEUTICS, INC., 3611 VALLEY CENTRE DRIVE, SUITE 300, SAN DIEGO CA 92130 |
Noah L. Rosenberg | officer: Chief Medical Officer | C/O ESPERION THERAPEUTICS, INC., 46701 COMMERCE CENTER DRIVE, PLYMOUTH MI 48170 |
Suzanne Louise Bruhn | director | C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S. MOPAC EXPRESSWAY, SUITE 250, AUSTIN TX 78746 |
From GuruFocus
By Marketwired • 01-06-2025
By Marketwired • 03-12-2025
By GuruFocus News • 02-21-2025
By Marketwired • 02-24-2025
By Marketwired • 01-13-2025
By GuruFocus News • 02-11-2025
By Marketwired • 02-13-2025
By GuruFocus News • 02-20-2025
By GuruFocus News • 01-31-2025
By GlobeNewswire • 02-12-2025
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.